Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
Healthcare
$97.81 -0.08%
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
52W Low $3.43High $47.84
Volume 0.74M
Average 1.10M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$234.39M
FY 2025 · Annual
Net Income
-$229.97M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 8.71M | 11M | 25.95M | 26.71M | 0 |
| Gross Profit | (8.71M) | (11M) | (25.95M) | (26.71M) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 217.34M | 267.59M | 206.3M | 126.1M | 182.37M |
| Selling, General & Admin | 41M | 62.79M | 71.02M | 34.05M | 52.02M |
| Operating Expenses | 258.34M | 330.38M | 251.37M | 160.14M | 234.39M |
| Depreciation & Amortization | 8.71M | 11M | 25.95M | 26.71M | 26.32M |
| EBITDA | (258.26M) | (322.8M) | (234.53M) | (149.5M) | (203.65M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (267.05M) | (341.38M) | (277.32M) | (186.85M) | (234.39M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 298K | 7.07M | 16.73M | 11.15M | 4.52M |
| Interest Expense | 22K | 18K | 13K | 0 | 0 |
| Other Income / Expenses | 61K | 7.56M | 16.83M | 10.64M | 4.42M |
| Income Before Tax | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.16) | (6.39) | (4.97) | (3.35) | (4.32) |
| EPS (Diluted) | (5.16) | (6.39) | (4.97) | (3.35) | (4.32) |
| 51.79M | 52.25M | 52.41M | 52.58M | 53.21M | |
| 51.79M | 52.25M | 52.41M | 52.58M | 53.21M |
KOD Earnings Waterfall · TTM
NASDAQ:KOD · Revenue to Net Income
Key Ratios
EPS$-4.08
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-12.2
P/S Ratio0.0
Analysis
$0 of revenue converted into -$246.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.08, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 23, 2026 |
How much revenue does KOD generate?
Kodiak Sciences Inc. (KOD) reported $0.00 of revenue in fiscal 2025.
Is KOD profitable?
Kodiak Sciences Inc. (KOD) reported -$229.97M of net income.
Continue the stock analysis
Jump to another research area for this company.